Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease

doi:10.3390/books978-3-0365-7684-8

Download Url(s)

https://mdpi.com/books/pdfview/book/7293

Contributor(s)

Vesa, Cosmin Mihai (editor)

Bungau, Simona Gabriela (editor)

Language

English

Show full item record

Abstract

The purpose of this reprint based on the Special issue "Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease”, IJMS journal, MDPI, is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease.

URI

https://directory.doabooks.org/handle/20.500.12854/100830

Keywords

nicotinamide mononucleotide; retinal ischemia/reperfusion; oxidative stress; neuroprotection; inflammation; sacubitril/valsartan; mortality; morbidity; heart failure; ejection fraction; diabetes mellitus; α-glucosidase; abietane diterpenoids; levopimaric acid; quinopimaric acid; molecular docking; ADMET; PFK15 synthesis; sunitinib L-malate; HUVEC; angiogenesis; synergy; cardiovascular medicine; diabetes; hypertension; GIP; GLP-1; glucagon; incretins; LY3298176; meta-analysis; obesity; SUMMIT; SURMOUNT; SURPASS; SYNERGY; Tirzepatide; common carotid artery occlusion; retinal ischemia; dyslipidemia; statin; children; adolescents; metabolic syndrome; liver; hsa-miR-193b-3p; peroxisome proliferator activated receptor gamma coactivator 1 alpha; lipid metabolism; n/a; empagliflozin; type 2 diabetes mellitus; leptin; sphingolipids; sphingomyelinase; vasorelaxation; endothelial nitric oxide synthase; type 2 diabetes; thromboxane prostanoid receptor